© Copyright ClearPath Benefits

Newer FDA-approved novel immunotherapies have shown to be beneficial responses to colorectal cancer, but at staggering costs that can be upward of $400,000 per year, according to the National Cancer Institute. This post from Employee Benefit News discusses incorporating cancer screenings into corporate wellness programs....